Fundraising Fox
Newpathmolecular
2 known investors
Find your way into Newpathmolecular
Sign up to see every warm intro you have to Newpathmolecular
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Newpathmolecular team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
New Path Molecular develops drug conjugates targeting phosphatidylserine on cancer cell membranes to treat solid tumors with reduced toxicity to healthy tissue. The company's lead program, PDC-1, is designed to treat colorectal and pancreatic cancer and is advancing toward clinical candidate selection.
Investors · 2
Frequently asked questions
- What does Newpathmolecular do?
- New Path Molecular develops drug conjugates targeting phosphatidylserine on cancer cell membranes to treat solid tumors with reduced toxicity to healthy tissue. The company's lead program, PDC-1, is designed to treat colorectal and pancreatic cancer and is advancing toward clinical candidate selection.
- Who are Newpathmolecular's investors?
- Newpathmolecular's investors include Deepbridge Capital, Oxford Investment Opportunity Network (OION).